The effect of different apo(a) isoforms on plasminogen activation in black South African subjects

Cardiovascular Journal of South Africa

Volumn 14, Issue 3, 2003, Pages 120-124

  Choma, Solomon R ^a   Alberts, Marianne ^a   Potgieter, Hendrick C ^b   Ojwang, Peter J ^c  

^a UNIVERSITY OF LIMPOPO   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; PLASMINOGEN;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CARDIOVASCULAR RISK; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MOLECULAR SIZE; NEGRO; NORMAL HUMAN; PHENOTYPE; PLASMINOGEN ACTIVATION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RISK FACTOR; RURAL AREA; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PARTICLE SIZE; PROBABILITY; PROTEIN ISOFORMS; RISK FACTORS; RURAL POPULATION; SOUTH AFRICA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0041972615     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Berg K. A new type system in man - The Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-373.
2. Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen. Q J Med 2000; 93(2): 75-84.
3. Schulter V, Koolwijk P, Peters E, Frank S, Hrzenjak A, Graier WF, van Hinsberg VW, Kostner GM. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21(3): 433-438.
4. Paulter F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L. High levels of Lp(a) with small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000; 20(12): 2619-2624.
5. Von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrentforth S. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-3368.
6. Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, Fruchart JC. Isolation and characterization of two sub-species of Lp(a), one containing apoE and one free of apo E. Biochim Biophys Acta 1992; 1127(2): 124-130.
7. Bach-Ngohou K, Giraud F, Krempf M, Bard JM. Infleunce of remnant accumulation markers on plasma concentration of two lipoprotein(a) sub-species (containing or free of apo E). Metabolism 2001; 50(3): 277-282.
8. Eaton DL, Fless GM, Kohr W, Mclean JW, Xu Q, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.
9. Mclean JW, Tomlison JE, Kuang W, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologus to plasminogen. Nature 1987; 300: 132-137.
10. Hervio L, Brunner C, Sorell L, Kang C, Muller H, Angeles-Cano E. Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen cleavage site. Biochim Biophys Acta 1999; 1434(1): 124-134.
11. Testa R, Marcovina SM. The rate of plasmin formation in vitro is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 1999; 29(3): 128-132.
12. Karadi I, Kostner GM, Gries A, Nimpf J, Romics L, Malle E. Lipoprotein(a) and plasminogen are immunologically related. Biochim Biophys Acta 1988; 960: 91-97.
13. Aznar J, Estelles A, Breto M, Espana F, Alos T. Euglobin clot lysis induced by tissue plasminogen activator is reduced in subjects with increased levels of lipoprotein(a). Thromb Res 1992; 66: 569-582.
14. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-2374.
15. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue plasminogen activation. Thromb Res 1990; 57: 55-62.
16. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA mediated glu-plasminogen activation. Biochemistry 1995; 34: 5151-5157.
17. Mao SJ, Tucci MA. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Letts 1990; 267: 131-134.
18. Halvorsen S, Skjonberg OH, Berg K, Ruyter R, Godal HC. Does lipoprotein(a) lipoprotein inhibit the fibrinolytic system? Thromb Res 1992; 68: 223-232.
19. Lui J, Harpel PC, Panell R, Gurewich V. Lipoprotein(a): A kinetic study of its influence on fibrin-dependent plasminogen activation by pro-urokinase or tissue plasminogen activator. Biochemisry 1993; 32: 9694-9700.
20. Pekelharing HLM, Kleinveld HA, Duif PFC, Bouma BN, Van Rijn HJM. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix dependent plasminogen activation by tissue plasminogen activator. Thromb Res 1996; 75(3): 497-502.
21. Hervio L, Girard-Globa A, Durlach V, Angeles-Cano E. Antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996; 26: 411-417.
22. Leerink CB, Duif PFC, Verhoeven N, Hackenberg CM, Prins LJ, Bouma BN, van Rijn HJM. Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin-modified des-AA-fibrinogen. Fibrinolysis 1994; 8: 214-220.
23. Kamboh MI, Ferell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991; 49: 1063-1074.
24. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem. 1994; 40(3): 400-403.
25. Carsten ME, Burgess LJ, Taljaard JJ. Lp(a) levels and apo(a) phenotypes in urban black South African men. S Afr Med J 1998; 88(2): 139-142.
26. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerewinkel E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in the 7 ethnic groups. Hum Genet 1991; 86: 607-614.
27. Kraft HG, Lingenhel A, Pang RW, Delport R, Trommsdorf M, Vermaak H, Janu ED, Utermann G. Frequency distribution of the apolipoprotein(a) kringle IV alleles and their effects on lipoprotein(a) levels in Caucasians, Asian and African populations: Distribution of null alles is non-random. Eur J Hum Genet 1996; 4: 74-78.
28. Utermann G, Menzel HJ, Kraft GH, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: Inheritance and relationship to Lp(a) concentrations in plasma. J Clin Invest 1987; 80: 458-465.
29. Rotimi CN, Cooper RS, Marcovina SM, McGee D, Owoaje E, Ladipo M. Serum distribution of lipoprotein(a) in African Americans and Bigerians: potential evidence for a genotype-enviromental effect. Genet Epidemiol 1997 14(2): 157-168.
30. Trommsdorf M, Koch S, Lingenhel A, Kroneberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G. A pentanucleotide repeat polymorphism n the 5′-control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995; 96: 150-157.
31. Seman LJ, de Luca C, Jenner JL. Isolation and purification of serum Lp(a) using lectin affinity. Methods Mol Biol 1998; 110: 131-136.
32. Liu JN, Kung W, Harpel PC, Gurewich V. Demonstration of covalent inding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells. Biochemistry 1998; 37(11): 3949-3954.
33. Ali S, Bunker CH, Aston CE, Ukoli FA, Kamboh MI. Apolipoprotein A kringle 4 polymorphism and serum lipoprotein(a) concentrations in African blacks. Hum Biol 1998; 70(3): 477-490.
34. Eisenthahl R, Danson MJ. In: Enzyme assays: A practical approach. New York: Oxford University Press, 1993: 277-313.
35. Oelofse A, Jooste PL, Steyn K. The lipid and lipoprotein profile of the urban black South African population of the Cape Peninsula - The Brisk study. S Afr Med J 1996; 86: 162-166.
36. Cappuccio FP. Ethnicity and cardiovascular risk: variations in people of African ancestry and South Asian origin. J Hum Hypertens 1997; 11(9): 571-576.
37. Hames CG, Greenlund KJ. Ethnicity and cardiovascular disease: The Evans County heart study. Am J Med Sci 1996; 311(3): 130-134.